Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice

Journal of Applied Toxicology

Volumn 35, Issue 2, 2015, Pages 142-151

  Takai, Shohei ^a   Higuchi, Satonori ^a   Yano, Azusa ^a   Tsuneyama, Koichi ^b   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a,c  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Flucloxacillin; IL 17; Inflammatory; Toll like receptor 4 (TLR4)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALGRANULIN A; CALGRANULIN B; CXCL1 CHEMOKINE; FLUCLOXACILLIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; ASPARTATE AMINOTRANSFERASES; FLOXACILLIN; GLUTATHIONE; HMGB1 PROTEIN; HMGB1 PROTEIN, MOUSE; INTERLEUKIN-17; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S100A8 PROTEIN, MOUSE; S100B PROTEIN, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; IN VIVO STUDY; LIMIT OF QUANTITATION; LIVER INJURY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMALS; BLOOD; CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; IMMUNOLOGY; LIVER; MICE; MICE, INBRED BALB C; PHYSIOPATHOLOGY; PROTEIN CARBONYLATION; REAL-TIME POLYMERASE CHAIN REACTION;

MUS;

ALANINE TRANSAMINASE; ANIMALS; ANTI-BACTERIAL AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CALGRANULIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FEMALE; FLOXACILLIN; GLUTATHIONE; HMGB1 PROTEIN; INTERLEUKIN-17; LIVER; MICE; MICE, INBRED BALB C; PROTEIN CARBONYLATION; REAL-TIME POLYMERASE CHAIN REACTION; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT;

EID: 84919859910     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3002     Document Type: Article

References (44)

1. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. 2010. Mechanisms of immune-mediated liver injury. Toxicol. Sci. 115: 307-321.
2. Andrade RJ, Tulkens PM. 2011. Hepatic safety of antibiotics used in primary care. J. Antimicrob. Chemother. 66: 1431-1446.
3. Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, Kitteringham NR, Park BK. 2009. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112: 521-531.
4. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. 2004. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J. Immunol. 172: 2522-2529.
5. Björnsson E, Olsson R. 2005. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42: 481-489.
6. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. 2008. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ. Res. 23: 1239-1246.
7. Carey MA, van Pelt FN. 2005. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 216: 41-48.
8. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP. 2009. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819.
9. De Filippo K, Henderson RB, Laschinger M, Hogg N. 2008. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J. Immunol. 180: 4308-4315.
10. Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP, 1995. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur. J. Clin. Pharmacol. 49: 81-85.
11. Dinarello CA. 2011. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur. J. Immunol. 41: 1203-1217.
12. Dugan CM, Fullerton AM, Roth RA, Ganey PE. 2011. Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxicol. Sci. 120: 507-518.
13. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. 2009. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86: 557-566.
14. Foell D, Wittkowski H, Vogl T, Roth J. 2007. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81: 28-37.
15. Gebhardt C, Németh J, Angel P, Hess J. 2006. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 72: 1622-1631.
16. Griffith OW. 1980. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106: 207-212.
17. Higuchi S, Kobayashi M, Yoshikawa Y, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2011. IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol. Lett. 200: 139-145.
18. Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2012. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol. Sci. 130: 4-16.
19. Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. 2002. A pivotal involvement of IFN-g in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J. 16: 1227-1236.
20. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ. 2009. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Invest. 119: 305-314.
21. Kaplowitz N. 2005. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4: 489-499.
22. Kobayashi E, Kobayashi M, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2009. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci. 111: 302-310.
23. Kobayashi M, Higuchi S, Mizuno K, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2010. Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. Toxicology 275: 50-57.
24. Kobayashi M, Higuchi S, Ide M, Nishikawa S, Fukami T, Nakajima M, Yokoi T. 2012. Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J. Appl. Toxicol. 32: 823-833.
25. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y. 2004. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5years application in Toyama Medical and Pharmaceutical University Hospital. Mod. Pathol. 17: 1141-1149.
26. Lakehal F, Dansette PM, Becquemont L, Lasnier E, Delelo R, Balladur P, Poupon R, Beaune PH, Housset C. 2001. Indirect cytotoxicity of flucloxacillin toward human biliary epitheliumvia metabolite formation in hepatocytes. Chem. Res. Toxicol. 14: 694-701.
27. Li L, Chen L, Hu L, Liu Y, Sun HY, Tang J, Hou YJ, Chang YX, Tu QQ, Feng GS, Shen F, Wu MC, Wang HY. 2011. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 54: 1620-1630.
28. Malhi H, Gores GJ, Lemasters JJ. 2006. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43: 31-44.
29. Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, Alfirevic A, Cederbrant K, Daly AK, French N, Pirmohamed M, Park BK, Naisbitt DJ. 2013. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57: 727-739.
30. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. 1992. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J. Hepatol. 15: 154-161.
31. Ranganath S, Ouyang W, Bhattarcharya D, Sha WC, Grupe A, Peltz G, Murphy KM. 1998. GATA-3-dependent enhancer activity in IL-4 gene regulation. J. Immunol. 161: 3822-3826.
32. Roche JK, Stone MK, Gross LK, Lindner M, Seaner R, Pincus SH, Obrig TG. 2008. Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab. Invest. 88: 1178-1191.
33. Russmann S, Kaye JA, Jick SS, Jick H. 2005. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 60: 76-82.
34. Sasaki E, Matsuo K, Iida A, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2013. A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism. Toxicol. Sci. 136: 250-263.
35. Sass G, Heinlein S, Agli A, Bang R, Schümann J, Tiegs G. 2002. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19: 115-120.
36. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. 2010. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28: 367-388.
37. Stachulski AV, Baillie TA, Park BK, Obach RS, Dalvie DK, Williams DP, Srivastava A, Regan SL, Antoine DJ, Goldring CE, Chia AJ, Kitteringham NR, Randle LE, Callan H, Castrejon JL, Farrell J, Naisbitt DJ, Lennard MS. 2013. The generation, detection, and effects of reactive drug metabolites. Med. Res. Rev. 33: 985-1080.
38. Törnhage CJ, Brunlöf G, Wallerstedt SM. 2009. Severe hepatotoxic adverse reaction in a healthy schoolgirl after treatment with flucloxacillin. Drug Healthc. Patient Saf. 1: 17-19.
39. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR. 2005. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201: 1135-1143.
40. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. 2001. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34: 101-108.
41. Verma S, Kaplowitz N. 2009. Diagnosis, management and prevention of drug-induced liver injury. Gut 58: 1555-1564.
42. Wuillemin N, Asam J, Fontana S, Krähenbühl S, Pichler WJ, Yerly D. 2013. HLA haplotype determines hapten or p-I T cell reactivity to flucloxacillin. J. Immunol. 190: 4956-4964.
43. Yano A, Higuchi S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2012. Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. Toxicology 293: 107-114.
44. Yohe HC, O'Hara KA, Hunt JA, Kitzmiller TJ, Wood SG, Bement JL, Bement WJ, Szakacs JG, Wrighton SA, Jacobs JM, Kostrubsky V, Sinclair PR, Sinclair JF. 2006. Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am. J. Physiol. Gastrointest. Liver Physiol. 290: 1269-1279.